SST and neuroendocrine neoplasm: As native somatostatin peptides have a very short half-life time (approximate 1–3 min; Sheppard et al., 1979), long-acting and highly potent somatostatin analogues are currently available for the treatment of acromegaly and neuroendocrine tumors, including octreotide (long-acting; LAR-OCT; Bauer et al., 1982) and Lanreotide (slow release or autogel; Bevan, 2005; Molitch, 2008).